Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy

BACKGROUND: An unmet need remains for safe and effective treatments to induce and maintain remission in inflammatory bowel disease (IBD) patients. The Janus kinase (JAK) inhibitor, tofacitinib, has demonstrated robust efficacy in ulcerative colitis patients although, like other systemic immunosuppre...

Descripción completa

Detalles Bibliográficos
Autores principales: Beattie, David T., Pulido-Rios, M. Teresa, Shen, Fei, Ho, Melissa, Situ, Eva, Tsuruda, Pam R., Brassil, Patrick, Kleinschek, Melanie, Hegde, Sharath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718031/
https://www.ncbi.nlm.nih.gov/pubmed/29225517
http://dx.doi.org/10.1186/s12950-017-0175-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718031/
https://www.ncbi.nlm.nih.gov/pubmed/29225517
http://dx.doi.org/10.1186/s12950-017-0175-2

Ejemplares similares